Nektar Therapeutics (NKTR) insider trading
Every open-market stock purchase and sale by Nektar Therapeutics executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $2M over the last 12 months (10 sales). No open-market buys.
- Last insider buy: Stephen K Doberstein (C-suite exec), $259K, 7 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $2M (10 sales). Last close $57.32 on Jun 4, 2026.
Recent NKTR insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 17, 2026 | Howard W Robin (CEO) | Sold | $334K |
| Jun 17, 2026 | Howard W Robin (CEO) | Sold | $277K |
| Jun 16, 2026 | Howard W Robin (CEO) | Sold | $318K |
| Jun 16, 2026 | Howard W Robin (CEO) | Sold | $285K |
| Jun 15, 2026 | Jonathan Zalevsky (Officer) | Sold | $336K |
| May 19, 2026 | Howard W Robin (CEO) | Sold | $29.1K |
| May 19, 2026 | Jonathan Zalevsky (Officer) | Sold | $13K |
| Feb 18, 2026 | Howard W Robin (CEO) | Sold | $30.9K |
| Feb 18, 2026 | Jonathan Zalevsky (Officer) | Sold | $13.1K |
| Jan 20, 2026 | Jonathan Zalevsky (Officer) | Sold | $138K |
| Dec 22, 2025 | Jonathan Zalevsky (Officer) | Bought (not open market) | — |
| Dec 22, 2025 | Jonathan Zalevsky (Officer) | Bought (not open market) | — |
| Dec 22, 2025 | Howard W Robin (CEO) | Bought (not open market) | — |
| Dec 22, 2025 | Howard W Robin (CEO) | Bought (not open market) | — |
| Nov 25, 2025 | Howard W Robin (CEO) | Sold | $120K |
| Nov 25, 2025 | Jonathan Zalevsky (Officer) | Sold | $62.8K |
| Nov 25, 2025 | Mark Andrew Wilson (C-suite exec) | Sold | $34.2K |
| Nov 21, 2025 | Jonathan Zalevsky (Officer) | Bought (not open market) | — |
| Nov 21, 2025 | Mark Andrew Wilson (C-suite exec) | Bought (not open market) | — |
| Nov 21, 2025 | Jonathan Zalevsky (Officer) | Bought (not open market) | — |
| Nov 21, 2025 | Howard W Robin (CEO) | Bought (not open market) | — |
| Nov 21, 2025 | Howard W Robin (CEO) | Bought (not open market) | — |
| Nov 21, 2025 | Mark Andrew Wilson (C-suite exec) | Bought (not open market) | — |
Who's trading NKTR
- Howard W Robin, CEO: sold $1.4M (7 sales), last Jun 17, 2026
- Jonathan Zalevsky, Officer: sold $563K (5 sales), last Jun 15, 2026
- Mark Andrew Wilson, C-suite exec: sold $34.2K (1 sale), last Nov 25, 2025
Get free alerts when an insider at Nektar Therapeutics files a new trade →